In this interview, Erik Magnus Ohman and Jane Margaret Armitage discuss ASCEND, a randomized trial of aspirin versus placebo for primary cardiovascular prevention in 15,480 people with diabetes.

Subscribe on iTunes | Subscribe on Google Play | Subscribe to ACCEL

Keywords: ACCELLite, ESC Congress, ESC18, Platelet Aggregation Inhibitors, Anticoagulants, Aspirin, Diabetes Mellitus, Hemorrhage, Intracranial Hemorrhages, Ischemic Attack, Transient, Metabolic Syndrome, Myocardial Infarction, Neoplasms, Primary Prevention, Stroke, Vascular Diseases, Angina, Stable

< Back to Listings